contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


publication-of-biohit-oyj-annual-report-2022-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Hvis de bare ville fremhæve, at L-cystein fra Acetium frigives med en kontrolleret hastighed lokalt i maven, mens cystein fra andre produkter er beregnet til at blive optaget fra tyndtarmen til blodbanen.

Meget glædelig nyhed! Dog, som du nævnte, har det nok ikke den store betydning endnu i forhold til euro. I 2024 var Biohits omsætning fra Finland i alt 0,2 millioner euro.

Sikkert ikke en nyhed, der vil forårsage en positiv resultatadvarsel, men for første gang i lang tid, tømmermænd + Acetium i en avisartikel. Så ingen anelse om, hvor meget salg der skal til, før grossisten ikke kan følge med.                  Helsingin Sanomat – 10 Dec 25              Alkoholi | Krapulan torjumiseen käytetty valmiste loppui tukusta    L-kysteiinin kysyntä on ollut kasvussa syksystä lähtien, kertovat apteekit.

Her er Antis kommentarer vedrørende den seneste GastroPanel-undersøgelse.  Biohit meddelte mandag om en ny klinisk undersøgelse, der understøtter GastroPanel-testens pålidelighed i at udelukke behovet for gastroskopi (mavesæksskopi). Nyheden understøtter selskabets væksthistorie og salgsargumenter, men forårsager ikke umiddelbare ændringer i vores prognoser.                   Inderes              Uusi tutkimus GastroPanelin hyödyistä hoidon ohjauksessa - Inderes    Tutkimus tukee  tukee GastroPanel-testin luotettavuutta gastroskopian (mahalaukun tähystyksen) tarpeen poissulkemisessa

Det er flot, at Gastropanel i år har 20-års jubilæum for sin markedsintroduktion, så det ville da også være på tide at slå stort igennem

I hvert fald ifølge denne pressemeddelelse:  “Op til 90 % af gastroskopierne kan undgås, når GastroPanel®-resultatet er normalt.”  Og endnu med adm. direktørens egne ord (i samme meddelelse) den samme påstand: Biohits administrerende direktør Jussi Hahtela: ”Resultaterne er meget tydelige: Når GastroPanel®-resultatet er normalt, er gastroskopi næsten aldrig nødvendig. Dette er et betydeligt vendepunkt, som muliggør betydelige omkostningsbesparelser og markant kortere ventetider på endoskopier.” Man skal selvfølgelig huske, at vi har hørt direktørers historier før (Biobone Substitutes, Faron Pharmaceuticals bl.a. om Traumakine osv. osv.). Denne gang lyder det hele dog helt vidunderligt. Selvfølgelig er der altid en mulighed for, at man om nogle år vil forstå, at også denne virksomheds direktørs historier skulle have været indtaget med en god portion salt =). Hovedejeren har tanket op med en rigtig stor skovl på det seneste, og insiderkøb betragtes vist generelt som et godt tegn. Efter min mening lyder denne nyhed, eller er i hvert fald blevet fremstillet til at lyde, rigtig god.

Antager du, at hver test og behandling, der udføres på hospitaler, er 100% nøjagtige/vellykkede? Her er der nu for eksempel i løbet af det sidste år kommet mange positive nyheder fra undersøgelser rundt om i verden, hvor GastroPanel tydeligt er blevet bevist som en fungerende løsning.

Biohit

Biohit Oyj Annual Financial Report March 22, 2023 at 09:30 am local time (EET)Biohit Oyj's Annual Report 2022 is published today in PDF and XHTML format. The annual report contains financial...

Biohit Oyj Annual Financial Report March 22, 2023 at 09:30 am local time (EET)Biohit Oyj's Annual Report 2022&nbsp;is published today in PDF&nbsp;and XHTML&nbsp;format. The annual report contains financial statements for 2022, the Report of the Board of Directors and Corporate Governance Statements. Information in ESEF format has not been audited. Annual report is published in Finnish and English, and it can be read and downloaded from Biohit company website:Annual Reports - Biohit Healthcare&nbsp;(<a href="https://www.biohithealthcare.com/en/investors/annual-reports/">https://www.biohithealthcare.com/en/investors/annual-reports/</a>)CEO&nbsp;Jussi Hahtela, Biohit Oyjtel. +358 9 773&nbsp;861 investor.relations@biohit.fi www.biohithealthcare.com&nbsp;(<a href="https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpublish.ne.cision.com%2Fl%2Fcutszctme%2Fwww.biohithealthcare.com%2Fen&amp;data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C1bee3e6161fa4dfad59608db2aa753f7%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C638150670738838689%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=eYIUhp%2Fsa9g9CfG47ZIlbfinDAseXQ0J2a1myjKucHQ%3D&amp;reserved=0">https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpublish.ne.cision.com%2Fl%2Fcutszctme%2Fwww.biohithealthcare.com%2Fen&amp;data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C1bee3e6161fa4dfad59608db2aa753f7%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C638150670738838689%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=eYIUhp%2Fsa9g9CfG47ZIlbfinDAseXQ0J2a1myjKucHQ%3D&amp;reserved=0</a>)Biohit in briefBiohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.&nbsp;www.biohithealthcare.com&nbsp;(<a href="https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpublish.ne.cision.com%2Fl%2Fcutszctme%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dc5rWyQltbzVNETEAzPUZ5WLkdGhFEQ1oTBo35iEHNX8xhFJ8UXxKcBfwNUj1oaJLkJWDIfhT0_qN_43uOPrHsIIWy25pE_7iX8aTY-nisGmlggNS87UH1ViJkQ-0ezca&amp;data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C1bee3e6161fa4dfad59608db2aa753f7%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C638150670738838689%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=yncFNzktqXBGKLDNNHxO82qUCwP%2BCbGlXM%2Fuh0qdcJI%3D&amp;reserved=0">https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpublish.ne.cision.com%2Fl%2Fcutszctme%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dc5rWyQltbzVNETEAzPUZ5WLkdGhFEQ1oTBo35iEHNX8xhFJ8UXxKcBfwNUj1oaJLkJWDIfhT0_qN_43uOPrHsIIWy25pE_7iX8aTY-nisGmlggNS87UH1ViJkQ-0ezca&amp;data=05%7C01%7CSanna.Kurlin%40biohit.fi%7C1bee3e6161fa4dfad59608db2aa753f7%7C4da67d2fc92245f9b72584364b1decf5%7C0%7C0%7C638150670738838689%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=yncFNzktqXBGKLDNNHxO82qUCwP%2BCbGlXM%2Fuh0qdcJI%3D&amp;reserved=0</a>)